Role of free radical in atherosclerosis, diabetes and dyslipidaemia: Larger-than-life

Diabetes/Metabolism Research and Reviews

Volumn 31, Issue 2, 2015, Pages 113-126

  Singh, Randhir ^a   Devi, Sushma ^a   Gollen, Rakesh ^b  

^a MAHARISHI MARKANDESHWAR DEEMED TO BE UNIVERSITY   (India)

^b LONG ISLAND UNIVERSITY   (United States)

Author keywords

Atherosclerosis; Diabetes; Dyslipidaemia; Free radicals; ROS

Indexed keywords

ANTIOXIDANT; DNA; FREE RADICAL; LIPID; NITRIC OXIDE; PROTEIN; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DISEASE COURSE; DYSLIPIDEMIA; HEART ARRHYTHMIA; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; TISSUE INJURY; AGING; ANIMAL; BIOLOGICAL MODEL; DYSLIPIDEMIAS; FOAM CELL; IMMUNOLOGY; METABOLISM;

AGING; ANIMALS; ATHEROSCLEROSIS; DIABETES MELLITUS; DYSLIPIDEMIAS; FOAM CELLS; HUMANS; MODELS, BIOLOGICAL; NITRIC OXIDE; OXIDATIVE STRESS; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN SPECIES;

EID: 84922592037     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.2558     Document Type: Review

References (171)

1. Nishide H, Suga T. Organic radical's battery. Electrochem Soc Interface 2005: 32-36.
2. Valdez LB, Arnaiz SL, Bustamante J, Alvarez S, Costa LE, Boveris A. Free radical chemistry in biological systems. Biol Res 2000: 33(2): 65-70.
3. Blake DR, Allen RE, Lunec J. Free radicals in biological systems-a review orientated to inflammatory processes. Br Med J 1987; 43: 371-385.
4. De Zwart LL, John H, Meerman N, et al. Biomarkers of free radical damage applications in experimental animals and in humans. Free Radic Biol Med 1999; 26: 202-226.
5. Inoue M, Sato EF, Nishikawa M. Mitochondrial generation of reactive oxygen species and its role in aerobic life. Curr Med Chem 2003; 10: 2495-2505.
6. Kumar S. Free radicals and antioxidants: Human and food system. Adv Appl Sci Res 2011; 2: 129-135.
7. Funda SP. K>ymet T. Free radicals: Our enemies or friends? Adv Appl Mol Biol 2007; 1: 63-69.
8. McCord JM, Fridovich I. Superoxide dismutase: an enzyme functions for erythromycin (haemocuprein). J Biol Chem 1969; 244: 6049-6055.
9. Karlsson J. Introduction to nutraology and radical formation. In Antioxidants and Exercise. Human Kinetics Press: Illinois, 1997; 1-143.
10. Landis GN, Tower J. Superoxide dismutase evolution and life span regulation. Mech Ageing Dev 2005; 126: 365-379.
11. Pastore A, Federici G, Bertini E, Piemonte F. Analysis of glutathione: Implication in redox and detoxification. Clin Chim Acta 2003; 333: 19-39.
12. Vasdev S, Gill VD, Singal PK. Modulation of oxidative stress induced changes in hypertension and atherosclerosis by antioxidants. Exp Clin Cardiol 2006; 11: 206-216.
13. Leonard SS, Harris GK, Shi XL. Metal-induced oxidative stress and signal transduction. Free Radic Biol Med 2004; 37: 1921-1942.
14. Valko M, Morris H, Cronin MT. Metals, toxicity and oxidative stress. Curr Med Chem 2005; 12: 1161-1208.
15. Chobot V, Hadacek F. Iron and its complexation by phenolic cellular metabolites from oxidative stress to chemical weapons. Plant Signal Behav 2010; 5: 1-5.
16. Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 2007; 39: 44-84.
17. Marnett LJ. Lipid peroxidation- DNA damage by malondialdehyde. Mut. Res-Fund. Mol Mech Muta 1999; b: 83-95.
18. Meagher EA, Barry OP, Lawson JA, Rokach J, FitzGerald GA. Effects of vitamin E on lipid peroxidation in healthy persons. JAMA 2001; 285: 1178-1182.
19. Huang HY, Appel LJ, Croft KD, Miller ER, Mori TA, Puddey IB. Effects of vitamin C and vitamin E on in vivo lipid peroxidation: results of a randomized controlled trial. Am J Clin Nutr 2002; 76: 549-555.
20. Brzezińska-Ślebodzińska E, Ślebodziński AB, Pietras B, Wieczorek G. Antioxidant effect of vitamin E and glutathione on lipid peroxidation in boar semen plasma. Biol Trace Elem Res 1995; 47: 69-74.
21. Biewenga GP, Guido RM, Haenen M, Bast A. The pharmacology of the antioxidant lipoic acid. Gen Pharmacol 1997; 29: 315-331.
22. Song K, Lee WJ, Koh J. α-Lipoic acid prevents diabetes mellitus in diabetes-prone obese rats. Biochem Biophys Res Commun 2004; 326: 197-202.
23. Turunen M, Olsson J, Dallner G. Metabolism and function of coenzyme Q. Biochim Biophys Acta 2004; 1660: 171-199.
24. Tomás-Zapico C, Coto-Montes A. Melatonin as antioxidant under pathological processes. Recent Pat Endocr Metab Immune Drug Discov 2007; 1: 63-82.
25. http://www.who.int/mediacentre/factsheets/fs317/en/.
26. Yusuf S, Ôunpuu S, Anand S. The global epidemic of atherosclerotic cardiovascular disease. Med Princ Prac 2002; 11: 3-8.
27. Frostegård J. Immunity, atherosclerosis and cardiovascular disease. BMC Med 2013; 11: 117-117.
28. Maria EL, Dennis JM, Stocker R. Actions of"antioxidants"in the protection against atherosclerosis. Free Radic Biol Med 2012; 53: 863-884.
29. Hansson GK. Inflammation, atherosclerosis and coronary artery disease. New Eng J Med 2005; 352: 1685-1695.
30. Cohen MP, Ziyadeh FN, Chen S. Amadori-modified glycated serum proteins and accelerated atherosclerosis in diabetes: Pathogenic and therapeutic implications. J Lab Clin Med 2006; 147: 211-219.
31. Stapleton PA, Goodwill AG, James ME, Brock RW, Frisbee JC. Hypercholesterolemia and microvascular dysfunction: Interventional strategies. J Inflamm 2010; 7: 54-54.
32. Vogiatzi G, Tousoulis D, Stefanadis C. The role of oxidative stress in atherosclerosis. Hellenic J Cardiol 2009; 50: 402-409.
33. Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation 2004; 109: III27-III32.
34. Fruchart JC, Duriez P. Free radicals and atherosclerosis. In Free Radical Damage and its Control, Rice-Evans CA, Burdon RH (eds). Elsevier Science: London, United Kingdom. 1994; 257-281.
35. Gerald HT. Daphne. LDL as a cause of atherosclerosis. Open Atheroscl Thromb J 2012; 5: 13-21.
36. Mimić-Oka J, Simić DV, Simić TP. Free radicals in cardiovascular diseases. Sci J FACTA UNIVERSITATIS Series: Med Biol 1999; 6: 11-22.
37. Prasad CVB, Kodliwadmath MV, Kodliwadmath GB. Erythrocyte superoxide dismutase, catalase activities and hydrogen peroxide induced lipid peroxidation in leprosy. Leprosy Rev 2007; 78: 391-397.
38. Maia MDS, Bicudo SD, Sicherle CC, Rodello L, Gallego ICS. Lipid peroxidation and generation of hydrogen peroxide in frozen-thawed ram semen cryopreserved in extenders with antioxidants. Ani Reprod Sci 2010; 122: 118-123.
39. Harris JD, Evans V, Owen JS. ApoE gene therapy to treat hyperlipidemia and atherosclerosis. Curr Opin Mol Ther 2006; 8: 1-13.
40. Chung M, Lichtenstein AH, Ip S, Lau J, Balk EM. Comparability of methods for LDL subfraction determination: a systematic review. Atherosclerosis 2009; 20: 342-348.
41. Howard SK, Huang W, Ishii I, Zhang WY. Macrophage foam cell formation with native low density lipoprotein. J Biol Chem 2002; 277: 34573-34580.
42. Louis SF, Zahradka P. Vascular smooth muscle cell motility: From migration to invasion. Exp Clin Cardiol 2010; 15: e75-e85.
43. Steven OM, Jain HT, Marks AR. Vascular smooth muscle cell proliferation in restenosis. Circulation: Cardiovasc Interv 2011; 4: 104-111.
44. Kaul N, Devaraj S, Jialal I. α-Tocopherol and Atherosclerosis. Exp Biol Med 2001; 226: 5-12.
45. Lim AK, Barry NP, Miyazaki-Anzai S, et al. ultimodal CARS microscopy determination of the impact of diet on macrophage infiltration and lipid accumulation on plaque formation in ApoE-deficient mice. J Lipid Res 2010; 51: 1729-1737.
46. Leonarduzzi G, Gamba P, Gargiulo S, Biasi F, Poli G. Inflammation-related gene expression by lipid oxidation-derived products in the progression of atherosclerosis. Free Radic Biol Med 2012; 52: 19-34.
47. González-Correa JA, Arrebola MM, Guerrero A, et al. Influence of vitamin E on the antiplatelet effect of acetylsalicylic acid in human blood. Platelets 2005; 16: 171-179.
48. Poredos P. Markers of preclinical atherosclerosis and their clinical relevance. Open Atheroscl Thromb J 2011; 4: 1-10.
49. Madamanchi NR, Runge MS. Mitochondrial Dysfunction in Atherosclerosis. Circ Res 2007; 100: 460-473.
50. Woo RA, McLure KG, Lees-Miller SP, Rancourt E. DNA-dependent protein kinase acts upstream of p53 in response to DNA damage. Nature 1998 Aug 13; 394(6694): 700-4.
51. Kozar RA, McKeone BJ, Pownall HJ. Free radical-induced alterations in endothelial cell function. J Surg Res 1994; 56: 32-36.
52. Van Lenten BJ, Navab M, Shih D, Fogelman AM, Lusis AJ. The role of high-density lipoproteins in oxidation and inflammation. Trends Cardiovasc Med 2001; 11: 155-161.
53. Navab M, Reddy ST, Van Lenten BJ, Anantharamaiah GM, Fogelman AM. The role of dysfunctional HDL in atherosclerosis. J Lipid Res 2009; 50: S145-S149.
54. Berry C, Tardif JC, Bourassa MG. Coronary Heart disease in patients with diabetes part I: recent advances in prevention and noninvasive management free. J Am Col Cardiol 2007; 49: 631-642.
55. Alfadda AA, Sallam RM. Reactive oxygen species in health and disease. J Biomed Biotech 2012; 2012: 1-14.
56. Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res 2010; 107: 1058-1070.
57. Wolff SP. Diabetes mellitus and free radicals. Free radicals, transition metals and oxidative stress in the aetiology of diabetes mellitus and complications. Br Med Bull 1993; 49: 642-652.
58. Shaath JS. Islet amyloid and selected trace elements among type 2 diabetes mellitus patients in Gaza city, Islamic University-Gaza 2012; 5: 33.
59. Kaneto H, Nakatani Y, Kawamori D, Miyatsuka T, Matsuoka T. Involvement of oxidative stress and the JNK pathway in glucose toxicity. Rev Diabetic Stud 2004; 1: 165-174.
60. Green K, Brand MD, Murphy MP. Prevention of mitochondrial oxidative damage as a therapeutic strategy in diabetes. Diabetes 2004; 53: S110-S118.
61. Robertson RP, Harmon J, Tran PO, Tanaka Y, Takahashi H. Glucose toxicity in beta-cells: type 2 diabetes, good radicals gone bad, and the glutathione connection. Diabetes 2003; 52: 581-587.
62. Robertson RP. Chronic Oxidative Stress as a Central Mechanism for Glucose Toxicity in Pancreatic Islet Beta Cells in Diabetes. J Biol Chem 2004; 279: 42351-42354.
63. Yoon JW, Jun HS. Autoimmune destruction of pancreatic beta Cells. Am Jf Ther 2005; 12: 580-591.
64. Arioglu E, Andewelt A, Diabo C, Bell M, Taylor SI, Gorden P. Clinical course of the syndrome of autoantibodies to the insulin receptor (type B insulin resistance): a 28-year perspective. Medicine (Baltimore) 2002; 81: 87-100.
65. Elbein SC. Perspective: the search for genes for type 2 diabetes in the post-genome era. Endocrinology 2002; 143: 2012-2018.
66. Santos MCS, Louzada RAN, Souza ECL, et al. Diabetes mellitus increases reactive oxygen species production in the thyroid of male rats. Endocrinol 2013; 13: 1930-1930.
67. Espinoza-Jiménez A, Peón AN, Terrazas LI. Alternatively activated macrophages in Types 1 and 2 Diabetes. Med Inflamm 2012; 2012: 1-10.
68. Fowler MJ. Microvascular and macrovascular complications of diabetes. Clin Diabetes 2008; 26: 77-82.
69. Cantor J, Haskins K. Interactions of macrophages and T cells in autoimmune diabetes. Drug Discov Today Dis Mech 2006; 3: 381-385.
70. Kaplan M, Aviram M, Hayek T. Oxidative stress and macrophage foam cell formation during diabetes mellitus-induced atherogenesis: Role of insulin therapy. Pharmacol Therape 2012; 136: 175-185.
71. De Kimpe SJ, Anggârd EE, Carrier MJ. Reactive oxygen species regulate macrophage scavenger receptor type I, but not type II, in the human monocytic cell line THP-1. Mol Pharmacol 1998; 53: 1076-1082.
72. Brownlee M. The pathobiology of diabetic complications a unifying mechanism. Banting Lecture 2004. Diabetes 2005; 54: 1615-1625.
73. Wolf G. Role of reactive oxygen species in angiotensin II-mediated renal growth, differentiation, and apoptosis. Antioxid Redox Signal 2005; 7: 1337-1345.
74. Lee KY, D'Acquisto F, Hayden MS, Shim JH, Ghosh S. PDK1 nucleates T cell receptor-induced signaling complex for NF-κB activation. Science 2005; 308: 114-118.
75. Fong DS, Aiello LP, Ferris FL, Klein R. Diabetic retinopathy. Diabetes Care 2004; 27: 2540-2553.
76. Oyama T, Miyasita Y, Watanabe H, et al. The role of polyol pathway in high glucose-induced endothelial cell damages. Diabetes Res Clin Pract 2006; 73: 227-234.
77. Oka M, Kato N. Aldose reductase inhibitors. J Enzyme Inhib 2001; 16: 465-473.
78. Hoehn KL, Salmon AB, Hohnen-Behrens C et al. Insulin resistance is a cellular antioxidant defense mechanism. Proc Natl Acad Sci USA 2009; 106(42); 17787-17792.
79. Desco MC, Asensi M, Ma'rquez R, et al. Xanthine oxidase is involved in free radical production in type 1 diabetes protection by allopurinol. Diabetes 2002; 51: 1118-1124.
80. Jan Škrha. Diabetes and vascular disease: From pathogenesis to treatment Are vascular effects of hypoglycemic and hypolipidemic drugs independent of their metabolic effects? Diabetes & Metabolic Syndrome. Clin Res Rev 2007; 1: 61-69.
81. Hadi HAR, Suwaidi JAI. Endothelial dysfunction in diabetes mellitus. Vasc Health Risk Manage 2007; 3: 853-876.
82. Shi Y, Vanhoutte PM. Reactive oxygen-derived free radicals are key to the endothelial dysfunction of diabetes. J Diabetes 2009; 1: 151-162.
83. Graier WF, Pusch K, Wascher T. Increased superoxide formation in endothelial cells during hyperglycemia. Diabetes Res Clin Pract 1999; 45: 153-160.
84. Cosentino F, Hishikawa K, Katusic ZS, Luscher TF. High glucose increases NOS expression and superoxide anion generation in human aortic endothelial cells. Circulation 1997; 96: 25-28.
85. Pierre K, Pellerin L. Monocarboxylate transporters in the central nervous system: distribution, regulation and function. J Neurochem 2005; 94: 1-14.
86. Thaler S, Choragiewicz TJ, Rejdak R, et al. Neuroprotection by acetoacetate and β-hydroxybutyrate against NMDA-induced RGC damage in rat-possible involvement of kynurenic acid. Graefe's Arch Clin Exp Ophthalmol 2010; 248: 1729-1735.
87. Umamaheswari M, Chatterjee TK. In-vitro antioxidant activities of the fractions of Coccinia grandis L. leaf extract. Afr J Tradit Complement Alternate Med 2008; 5: 61-73.
88. Mlakar A, Batna A, Dudda A, Spiteller G. Iron (II) ions induced oxidation of ascorbic acid and glucose. Free Rad Res 1996; 25: 525-539.
89. Ali Ebrahimzadeh M, Nabavia SM, Nabavia SF, Bahramianc F, Bekhradnia AR. Antioxidant and free radical scavenging activity of H. officinalis L. Var. Angustifolius, V. odorata, B. hyrcana and C. speciosum. Pak J Pharma Sci 2010; 23: 29-34.
90. Hunt JV, Wolff SP. Oxidative glycation and free radical production: a causal mechanism of diabetic complications. Free Rad Res Communication 1991; 12-13: 115-123.
91. Stadler K, Jenei V, Bolcsh'azy V, Somogyi A, Jakus J. Increased nitric oxide levels as an early sign of premature aging in diabetes. Free Radic Biol Med 2003; 35: 1240-1251.
92. Schleicher ED, Weigert C. Role of the hexosamine biosynthetic pathway in diabetic nephropathy. Kidney Int Suppl 2000; 77: S13-S8.
93. Dunlop M. Aldose reductase and the role of the polyol pathway in diabetic nephropathy. Kidney Int Suppl 2000; 58: S3-S12.
94. Koshikawa M, Mukoyama M, Mori K, et al. Role of p38 mitogen-activated protein kinase activation in podocyte injury and proteinuria in experimental nephrotic syndrome. J Am Soc Nephrol 2005; 16: 2690-2701.
95. Meier M, Menne J, Park JK, Haller H. Nailing down PKC isoform specificity in diabetic nephropathy-two's company, three's a crowd. Nephrol Dial Transplant 2007; 22: 2421-2425.
96. Nakajima H, Amano W, Kubo T, et al. Glyceraldehyde-3-phosphate dehydrogenase aggregate formation participates in oxidative stress-induced cell death-An external file that holds a picture, illustration, etc. J Biol Chem 2009; 284: 34331-34341.
97. Maritim AC, Sanders RA, Watkins JB. Diabetes, oxidative stress, and antioxidants: a review. J Biochem Mol Toxicol 2003; 17: 24-38.
98. Blázovics A, Fehér E, Fehér J. Role of Free Radical Reactions in Experimental Hyperlipidemia in the Pathomechanism of Fatty Liver. Free Radicals and the Liver.
99. Peterson TE. Poppa V, Ueba H, Wu A, Yan C, Berk BC. Opposing effects of reactive oxygen species and cholesterol on endothelial nitric oxide synthase and endothelial cell caveolae. Circulation Res 1999; 85: 29-37. 1992; 96-123.
100. Roberts WC. Preventing and arresting coronary atherosclerosis. Am Heart J 1995; 130: 580-600.
101. Koter M, Franiak I, Strychalska K, Broncel M, Chojnowska-Jezierska J. Damage to the structure of erythrocyte plasma membranes in patients with type-2 hypercholesterolemia. Int J Biochem Cell Biol 2004; 36: 205-215.
102. Schaffer SW, Jong CJ, Mozaffari M. Role of oxidative stress in diabetes-mediated vascular dysfunction: Unifying hypothesis of diabetes revisited. Vas Pharmacol 2012; 57: 139-149.
103. O'Keefe JH, Bell DSH. Postprandial hyperglycemia/hyperlipidemia (Postprandial Dysmetabolism): Is a Cardiovascular Risk Factor. Am J Cardiol 2007; 100: 899-904.
104. Ónody A, Csonka C, Giricz Z, Ferdinandy P. Hyperlipidemia induced by a cholesterol-rich diet leads to enhanced peroxynitrite formation in rat hearts. Cardiovas Res 2003; 58: 663-670.
105. Vira'g L, Szabo' E, Gergely P, Szabo C. Peroxynitrite-induced cytotoxicity: mechanism and opportunities for intervention. Toxicol Lett 2003; 140: 113-124.
106. Hrabarova E, Juranek I, Soltes L. Pro-oxidative effect of peroxynitrite regarding biological systems: a special focus on high-molar-mass hyaluronan degradation. Gen Physiol Biophy 2011; 30: 223-238.
107. Miller MR, Megson IL. Recent developments in nitric oxide donor drugs. Br J Pharmacol 2007; 151: 305-321.
108. Yang R. Effect of antioxidant capacity on blood lipid metabolism and lipoprotein lipase activity of rats fed a high-fat diet. Nutrition 2006; 22: 1185-1191.
109. Condell RA. Evidence for suitability of glutathione peroxidase as a protective enzyme: studies of oxidative damage, restoration and proteolysis. Arch Biochem Biophys 1983; 223: 407-416.
110. Thomas MJ. Physiological aspects of low-density lipoprotein oxidation. Curr Opin Lipidol 2000; 11: 297-301.
111. Keevil JG. Implications of cardiac risk and low-density lipoprotein cholesterol distributions in the United States for the diagnosis and treatment of dyslipidemia: data from National Health and Nutrition Examination Survey 1999 to 2002. Circulation 2007; 115: 1363-1370.
112. Andrew PJ, Mayer B. Enzymatic function of nitric oxide synthases. Cardiovas Res 1999; 43: 521-531.
113. Knowles JW, Reddick RL, Jennette JC, Shesely EG, Smithies O, Maeda N. Enhanced atherosclerosis and kidney dysfunction in eNOS(-/-)Apoe(-/-) mice are ameliorated by enalapril treatment. J Clin Invest 2000; 105: 451-458.
114. Kuhlencordt PJ, Chen J, Han F, Astern J, Huang PL. Genetic deficiency of inducible nitric oxide synthase reduces atherosclerosis and lowers plasma lipid peroxides in apolipoprotein E-knockout mice. Circulation 2001; 103: 3099-3104.
115. Lowenstein CJ. Beneficial Effects of Neuronal Nitric Oxide Synthase in Atherosclerosis. Arterioscler Thromb Vasc Biol 2006; 26: 1417-1418.
116. Soski S, Dobutovi BD, Sudar EM, et al. Regulation of inducible nitric oxide synthase (inos) and its potential role in insulin resistance, diabetes and heart failure. Open Cardiovas Med J 2011; 5: 153-163.
117. Thippeswamy T, McKay JS, Quinn JP, Morris R. Nitric oxide, a biological double-faced janus--is this good or bad? Histol Histopath 2006; 21: 445-458.
118. Beckman JS, Koppenol WH. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol 1996; 271: C1424-C1437.
119. Rubbo H, Batthyany C, Radi R. Nitric oxide-oxygen radical interactions in atherosclerosis. Biol Res 2000; 33: 167-175.
120. Jeremy JY, Rowe D, Emsley AM, Newby AC. Nitric oxide and the proliferation of vascular smooth muscle cells. Cardiovas Res 1999; 43: 580-594.
121. Chiang TM, Woo-Rasberry V. Effect of nitric oxide on platelet progeneitor growth, posttranslational modification of protein, and function. Open Nitric Oxide J 2008; 1: 1-4.
122. Sethi S, Sharma P, Dikshit M. Nitric oxide and oxygen derived free radical generation from control and lipopolysaccharide-treated rat polymorphonuclear leukocyte. Nitric Oxide 2001; 5: 482-493.
123. Cooke JP. Role of nitric oxide in progression and regression of atherosclerosis. West J Med 1996; 164: 419-424.
124. Barter PJ, Nicholls S, Rye KA, Anantharamaiah GM, Navab M, Fogelman AM. Antiinflammatory properties of HDL. Circulation Res 2004; 95: 764-772.
125. Zheng L, Nukuna B, Brennan ML, et al. Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest 2004; 114: 529-541.
126. Rivera J, Lozano ML, Navarro-Núñez L, Vicente V. Platelet receptors and signaling in the dynamics of thrombus formation. Haematologica 2009; 94: 700-711.
127. Etsuo N. Do free radicals play causal role in atherosclerosis? Low density lipoprotein oxidation and vitamin E revisited. J Clin BioNut 2011; 48: 3-7.
128. Omawari N, Dewhurst M, Vo P, Mahmood S, Stevens E, Tomlinson DR. Deficient nitric oxide responsible for reduced nerve blood flow in diabetic rats: effects of L-NAME, L-arginine, sodium nitroprusside and evening primrose oil. Br J Pharmacol 1996; 118: 186-190.
129. Cosenzi A, Bernobich E, Bonavita M, Trevisan R, Bellini G, Campanacci L. Early effects of diabetes on inducible nitric oxide synthase in the kidney. Acta Diabetol 2002; 39: 91-96.
130. Sokolovska J, Isajevs S, Baumanea L, et al. P5: Enhanced expression of xanthine oxidase and NO synthases causing the overproduction of NO in kidneys of diabetic animals can be reduced by 1, 4-dihydropyridines. Nitric Oxide 2013; 31: S1-S15.
131. Kincer JF, Uittenbogaard A, Dressman J, et al. Hypercholesterolemia promotes a CD36-dependent and endothelial nitric-oxide synthase-mediated vascular dysfunction. J Biol Chem 2002; 277: 23525-23533.
132. Aronson D, Rayfield EJ. How hyperglycemia promotes atherosclerosis: molecular mechanisms. Cardiovas Diabetol 2002; 1: 1-10.
133. Cade WT. Diabetes-related microvascular and macrovascular diseases in the physical therapy setting. Phy Ther 2008; 88: 1322-1335.
134. Bierman EL. Atherogenesis in diabetes. Arteriosclero Thromb 1992; 12: 647-656.
135. Jay D, Hitomi H, Griendling KK. Oxidative stress and diabetic cardiovascular complications. Free Radic Biol Med 2006; 40: 183-192.
136. Roche LD, AcostaMedina E, Pe'rez AF, et al. Lipofundin-Induced hyperlipidemia promotes oxidative stress and atherosclerotic lesions in new zealandwhite rabbits. Int J Vas Med 2012; 2012: 1-7.
137. Yang RL, Shi YH, Hao G, Li W, Le GW. Increasing oxidative stress with progressive hyperlipidemia in human: Relation between malondialdehyde and atherogenic. J Clin Biochem Nut 2008; 43: 154-158.
138. Renard CB, Kramer F, Johansson F. Diabetes and diabetes-associated lipid abnormalities have distinct effects on initiation and progression of atherosclerotic lesions. J Clin Invest 2004; 114: 659-668.
139. Renard C, Van Obberghen E. Role of diabetes in atherosclerotic pathogenesis. What have we learned from animal models? Diabetes Metabol 2006; 32: 15-29.
140. Lee SC. Uncoupling protein-2 modulation of reactive oxygen species and cell viability in the pancreatic beta cell, 2008; 1-17.
141. Ceriello A, Motz E. Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? Arteriosclerosis Thromb Vasc Biol 2004; 24: 816-823.
142. Pastromas S, Terzi AB, Tousoulis D, Koulouris S. Postprandial lipemia: An under-recognized atherogenic factor in patients with diabetes mellitus. Int J Cardiol 2008; 126: 3-12.
143. Atabek EM, Selim K, Ozgur P, Murat B. Arterial wall thickening and stiffening in children and adolescents with type 1 diabetes. Diabetes Res Clin Prac 2006; 74: 33-40.
144. Mario B, Assunta P, Di PN, et al. Adherence of uremic erythrocytes to vascular endothelium decreases endothelial nitric oxide synthase expression. Kidney Int 2005; 67: 1899-1906.
145. Alemany M. Regulation of adipose tissue energy availability through blood flow control in the metabolic syndrome. Free Radic Biol Med 2012; 52: 2108-2119.
146. Price KD, Catherine SC, Price B, Reynolds RD. Hyperglycemia-induced ascorbic acid deficiency promotes endothelial dysfunction and the development of atherosclerosis. Atherosclerosis 2001; 158: 1-12.
147. Shao N, Kuang HY, Wang N, et al. Relationship between oxidant/antioxidant markers and severity of microalbuminuria in the early stage of nephropathy in type 2 diabetic patients. J Diabetes Res 2013; 2013: 1-6.
148. Palinski W, Napoli C. The fetal origins of atherosclerosis: Maternal hypercholesterolemia, and cholesterol-lowering or antioxidant treatment during pregnancy influence in utero programming and postnatal susceptibility to atherogenesis. FAS Exper Biol J 2002; 16: 1348-1360.
149. Giardino I, Edelstein D, Brownlee M. BCL-2 expression or antioxidants prevent hyperglycemia-induced formation of intracellular advanced glycation end products in bovine endothelial cells. J Clin Invest 1996; 97: 1422-1428.
150. Takei A, Huang Y, Lopes-Virella F. Intercellular adhesion molecule-1 (ICAM-1) expression induced by oxLDL on human umbilical vein endothelial cells (HUVEC) depends on the stage of LDL oxidation. Diabetes 1998; 47: A115-A115.
151. Leopold JA, Loscalzo J. Oxidative risk for atherothrombotic cardiovascular disease. Free Radic Biol Med 2009; 47: 1673-1706.
152. Nishikawa T, Edelstein D, Du XL, et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycemic damage. Nature 2000; 404: 787-790.
153. Wolff SP. Diabetes mellitus and free radicals. Free radicals, transition metals and oxidative stress in the aetiology of diabetes mellitus and complications. Br Med Bull 1993; 49: 642-652.
154. Baynes JW, Thorpe SR. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 1999; 48: 1-9.
155. Kangralkar VA, Patil SD, Bandivadekar RM. Oxidative stress and diabetes: a review. Int J Pharma App 2010; 1: 38-45.
156. Mrakic-Sposta S, Gussoni M, Montorsi M, Porcelli S, Vezzoli A. Assessment of a standardized ROS production profile in humans by electron paramagnetic resonance. Oxid Med Cell Longevity 2012; 2012: 1-10.
157. Funk SD, Jr AY, Orr AW. Hyperglycemia and endothelial dysfunction in atherosclerosis: Lessons from Type 1 Diabetes. Int J Vasc Med 2012; 2012: 1-19.
158. Rocha MR, García-Bou R, Enguix N, Hernández-Mijares A, Esplugues JV, Víctor VM. Mitochondria-targeted Vitamin E antioxidant: An agent for cardiovascular protection. Vasc Dis Prev 2009; 6: 36-46.
159. Johansen JS, Harris AK, Rychly DJ, Ergul A. Oxidative stress and the use of antioxidants in diabetes: Linking basic science to clinical practice. Cardiovas Diabetol 2005; 4: 1-11.
160. Fu L, Xu BT, Xu XR, et al. Antioxidant capacities and total phenolic contents of 62 fruits. Food Chem 2011; 129: 345-350.
161. Cai YZ, Luo Q, Sun M, Corke H. Antioxidant activity and phenolic compounds of 112 traditional Chinese medicinal plants associated with anticancer. Life Sci 2004; 74: 2157-2184.
162. Gan RY, Kuang L, Xu XR, Zhang Y, Xia EQ, Song FL. Screening of natural antioxidants from traditional Chinese medicinal plants associated with treatment of rheumatic disease. Molecules 2010; 15: 5988-5997.
163. Ghasemzadeh A, Jaafar HZE, Rahmat A. Antioxidant activities, total phenolics and flavonoids content in two varieties of Malaysia young ginger (Zingiber officinale Roscoe). Molecules 2010; 15: 4324-4333.
164. Li HB, Cheng KW, Wong CC, Fan KW, Chen F, Jiang Y. Evaluation of antioxidant capacity and total phenolic content of different fractions of selected microalgae. Food Chem 2007; 102: 771-776.
165. Li HB, Wong CC, Cheng KW, Chen F. Antioxidant properties in vitro and total phenolic contents in methanol extracts from medicinal plants. Food Sci Tech 2008; 41: 385-390.
166. Stangeland T, Remberg SF, Lye KA. Total antioxidant activity in 35 Ugandan fruits and vegetables. Food Chem 2009; 113: 85-91.
167. Wong CC, Li HB, Cheng KW, Chen F. A systematic survey of antioxidant activity of 30 Chinese medicinal plants using the ferric reducing antioxidant power assay. Food Chem 2006; 97: 705-711.
168. Pattaneeya P, Reuthaithip S, Rin C, et al. Amelioration of hyperglycemia, hyperlipidemia, oxidative stress and inflammation in steptozotocin-induced diabetic rats fed a high fat diet by riceberry supplement. J Functional Foods 2013; 5: 195-203.
169. Jung EH, Kim SR, Hwang IK, Youl HT. Hypoglycemic effects of a phenolic acid fraction of rice bran and ferulic acid in C57BL/KsJ-db/db mice. J Agri Food Chem 2007; 55: 9800-9804.
170. Brambilla D, Mancuso C, Scuderi MR, et al. The role of antioxidant supplements in immune system, neoplastic, and neurodegenerative disorders: a point of view for an assessment of the risk/benefit profile. Nut J 2008; 7: 1-9.
171. Mosca L, Marcellini S, Perluigi M, et al. Biochem Pharmacol 2002; 63: 1305-1314.